Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma

VAŠKŮ, Vladimír, Anna VAŠKŮ and Julie BIENERTOVÁ VAŠKŮ. Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma. International Journal of Clinical and Experimental Pathology. USA: e-Century Publishing Corporation, Madiso, 2009, 2/2009, No 2, p. 163-168. ISSN 1936-2625.

Basic information

Original name

Pharmacogenetic Contribution of Leptin Gene Polymorphism in Cutaneous T-Cell Lymphoma

Name in Czech

Farmakogenetický příspěvek polymorfismu v genu pro leptin u kožních T-lymfomů

Authors

VAŠKŮ, Vladimír (203 Czech Republic, guarantor), Anna VAŠKŮ (203 Czech Republic) and Julie BIENERTOVÁ VAŠKŮ (203 Czech Republic)

Edition

International Journal of Clinical and Experimental Pathology, USA, e-Century Publishing Corporation, Madiso, 2009, 1936-2625

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

Genetics and molecular biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/09:00034200

Organization unit

Faculty of Medicine

UT WoS

000208021800006

Keywords in English

leptin; gene polymorphism; pharmacogenetics; cutaneous T-cell lymphoma

Tags

cutaneous T-cell lymphoma, Gene polymorphism, leptin, Pharmacogenetics

Tags

International impact, Reviewed

---

Abstract

V originále

Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.

In Czech

Abstract: Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.